LEO Pharma strengthens global leadership team
The company has set out on an ambitious growth journey to become a leading provider of innovative medicines helping patients with skin diseases. To align with its strategic objectives, it re-organizes its executive leadership team.
Dr. Monica Shaw, M.D., will assume the position of Executive Vice President, Region Europe+, effective July 1, 2020. Shaw joins LEO Pharma from GSK/ViiV Healthcare in Singapore, where she was VP Commercial, Head Asia Pacific region. She is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams and an extensive specialty experience within the pharmaceutical industry including in dermatology, immuno-inflammation and rare diseases. She has held several leadership positions internationally in Europe, Asia and Latin America.
“Monica Shaw’s experience in biologics, dermatology and specialty pharma will help us to be successful in our move to launch innovative treatments and become a global leader in medical dermatology. Her combination of global experience, great leadership skills and clinical background will contribute significantly to reach our ambitions,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Nathalie Joannes will join LEO Pharma as Executive Vice President, Legal and Compliance and General Counsel from September 1, 2020. She joins LEO Pharma from Roquette Freres’ headquarters in Paris, where she has been Group General Counsel. During Joannes’ long-standing career as general counsel in the life-sciences and pharmaceutical industries, she successfully built international teams in legal, risk management and compliance in publicly traded and privately owned, global companies. She holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar.
“Nathalie Joannes has a proven track record in counseling global companies and her global pharma and life-science industry experience will be of great value for LEO Pharma on its way to become a leading provider of innovative medicines. She is a highly experienced lawyer and builder of strong international teams, which will help us immensely,” said Mazzacco.
Effective July 1, 2020, Guillaume Clemént, currently Executive Vice President, Region Europe+, will assume responsibility for Region International and the thrombosis business, after having successfully led Region Europe+ in the last four years.
Official bios
Monica Shaw
Dr. Monica Shaw, M.D., is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams to deliver business performance and successful drug development. Monica Shaw has extensive specialty experience within the pharma industry working within dermatology, immuno-inflammation, HIV, neurology and oncology. She has held several leadership positions in the global pharma industry located in i.e. Europe, Asia and Latin America.
Monica Shaw earned an M.D. M.A. and is a Member of the Royal College of Physicians.
Employment History
VP Commercial Head Asia Pacific region, GSK/ViiV Healthcare
2018 to current
General Manager, GlaxoSmithKline
2016 – 2018
VP Global Franchise Medical Head for Specialty, GlaxoSmithKline
2014 – 2016
UK Chief Scientific Officer, Novartis
2013 – 2014
Global Therapy Area Director for Clinical Development and Business Development, Norgine
2011 – 2013
Global Clinical Director ADHD, Shire
2009 – 2011
Nathalie Joannes
Nathalie Joannes holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar since 1987. During her long-standing career as general counsel in the chemical and pharmaceutical industries, she successfully built international teams and guided listed pharma companies through the legal aspects of mergers & acquisitions, partnerships, high-risk litigations, anti-trust investigations, corporate governance and compliance.
Employment History
Group General Counsel, Roquette Frères
2016 to current
EVP and Group General Counsel, IPSEN
2011 – 2015
SVP and Chief European Counsel, Genzyme
2008 – 2011
General Counsel International, Cardinal Health
2007 – 2008
Group General Counsel, Serono International
2001 – 2007
Contacts
Henrik Kyndlev
+45 3140 6180
HDTDK@LEO-Pharma.com
Images
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
Annual report 2023: LEO Pharma delivers 10% revenue growth and returns to positive EBITDA29.2.2024 14:00:00 CET | Pressemeddelelse
Ballerup, February 29, 2024. – LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement. LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse
Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.
LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals23.1.2024 12:30:00 CET | Pressemeddelelse
Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology.
LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse
Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.
LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse
The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom